Ticker brief
MLTX
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
15
authors 14d
9
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-06-19 → 2026-06-24 · now -0.35 (−1 bearish … +1 bullish)
Who spoke9
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @BiopharmIQ | B | · | 4 | +0.18 |
| @bioinvestor24 | A | +1.35 | 2 | -0.22 |
| @ABBONews | C | · | 2 | +0.50 |
| @OpenOutcrier | C | · | 2 | -0.05 |
| @OzmosiHealth | C | · | 1 | +0.25 |
| @AlertsAndNews | C | +1.52 | 1 | +0.45 |
| @DekmarTrades | C | -1.16 | 1 | +0.00 |
| @HammerstoneMar3 | C | +0.56 | 1 | +0.50 |
| @buzztickr | C | · | 1 | +0.25 |
Recent signals15of 15 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-06-24 | @OpenOutcrier | -0.35 | MoonLake prices a $200M public offering at $20 per share. | · | tweet ↗ |
| 2026-06-22 | @buzztickr | +0.25 | Retail momentum watchlist with spotted/current prices, percentage changes and mention counts. | · | tweet ↗ |
| 2026-06-22 | @ABBONews | +0.50 | MLTX surged after encouraging 52-week Phase 3 VELA sonelokimab results. | · | tweet ↗ |
| 2026-06-22 | @BiopharmIQ | +0.35 | Biotech stock moves list with percentage changes and associated clinical/regulatory headlines. | · | tweet ↗ |
| 2026-06-22 | @HammerstoneMar3 | +0.50 | MoonLake shares up after Phase 3 VELA Week 52 results PR. | · | tweet ↗ |
| 2026-06-22 | @OpenOutcrier | +0.25 | MoonLake reports week 52 phase 3 trial data for sonelokimab. | · | tweet ↗ |
| 2026-06-22 | @DekmarTrades | +0.00 | References Week 52 phase 3 results for MLTX drug candidate without outcome detail. | · | tweet ↗ |
| 2026-06-22 | @ABBONews | +0.50 | MoonLake announced positive Phase 3 VELA results with strong HiSCR75/100 rates. | · | tweet ↗ |
| 2026-06-21 | @AlertsAndNews | +0.45 | MoonLake reports Week 52 Phase 3 VELA results with 67% HiSCR75 and remission metrics. | · | tweet ↗ |
| 2026-06-21 | @OzmosiHealth | +0.25 | MoonLake announced Week 52 Phase 3 VELA results and Investor Day. | · | tweet ↗ |
| 2026-06-21 | @BiopharmIQ | +0.15 | Identifies EVMN and MLTX as likely major catalyst events that can move stock by over 20%. | · | tweet ↗ |
| 2026-06-21 | @BiopharmIQ | +0.20 | Shows hedge fund ownership count for EVMN and MLTX at 8 of 36 funds. | · | tweet ↗ |
| 2026-06-21 | @BiopharmIQ | +0.00 | Biotech catalyst watchlist for Phase 2 and Phase 3 readouts in Q2/H1 2026. | · | tweet ↗ |
| 2026-06-19 | @bioinvestor24 | -0.10 | Contrasts ABBV/APGE immunology logic with MRK obesity strategy, criticizing MRK management. | · | tweet ↗ |
| 2026-06-19 | @bioinvestor24 | -0.35 | Calls IL17 a dying business and criticizes MRK interest in MLTX versus IL23/IL13 opportunities. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.